An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses

针对脑炎甲病毒的减毒活疫苗的知情方法

基本信息

项目摘要

ABSTRACT Eastern (EEEV), Venezuelan (VEEV), and Western (WEEV) equine encephalitis viruses are mosquito-transmitted alphaviruses with the potential to cause fatal neuroinvasive disease in humans and domesticated animals. These viruses also can be spread by the aerosol route and thus, have significant potential as biowarfare/bioterrorism agents. In 2019, EEEV human infections increased to levels not seen since the 1950s. Currently, there are no antiviral therapies or vaccines licensed for these alphaviruses. The existing investigational live-attenuated VEEV vaccine (LAV; TC-83) was generated >40 years ago, is highly reactogenic, poorly immunogenic, and causes disease in up to 20% of recipients. For EEEV and WEEV, investigational formalin-inactivated vaccines have been given to at-risk workers. While both elicit antibody responses, they provide uncertain protection and require multiple booster injections. A trivalent veterinary vaccine against VEEV, EEEV and WEEV is available but is so poorly immunogenic that domestic animals must be boosted annually and disease is seen in vaccinated animals. Here, we propose to develop safe and effective LAVs vaccine against these alphaviruses using recent advances in understanding of the virulence mechanisms of each. These advances will allow mutagenesis of pathogenicity domains that specifically reduce virulence, increase cytokine induction and antigen presentation and provide long-lasting protection. Furthermore, the mechanism of action of each mutation will be known and each will be specifically designed to resist reversion. We will combine mutations to create an optimal vaccine strain for each virus and then investigate their use in multivalent formulations, critical to veterinary vaccine development and highly desired for human formulations. We will identify correlates of protection for each vaccine and address the extent of cross-protection versus encephalitic viruses. For the first time with alphaviruses, the individual and combined effects of mutations with known mechanisms of action will be tested for effects on virus replication, disease and immunogenicity in animals.
摘要 东方(EEEV)、委内瑞拉(VEEV)和西方(WEEV)马脑炎病毒 是蚊子传播的甲病毒,有可能导致致命的神经侵入性疾病, 人类和家养动物的疾病。这些病毒也可以通过 气溶胶途径,因此具有作为生物战/生物恐怖主义制剂的巨大潜力。在 2019年,EEEV人类感染增加到自20世纪50年代以来未见的水平。目前, 目前还没有针对这些甲病毒的抗病毒疗法或疫苗。现有 研究性VEEV减毒活疫苗(LAV; TC-83)生产时间>40年 前,是高度反应原性,免疫原性差,并导致高达20%的疾病, 受惠人士对于EEEV和WEEV,研究用福尔马林灭活疫苗 给处于危险中的工人。虽然两者都能引起抗体反应,但它们提供了 不确定的保护,需要多次加强注射。三价兽用疫苗 抗VEEV、EEEV和WEEV的疫苗是可用的,但其免疫原性很差, 动物必须每年加强免疫,在接种疫苗的动物中发现疾病。这里我们 建议开发针对这些甲病毒的安全有效的LAV疫苗, 最近的进展,了解每一个毒力机制。这些 这些进展将允许特异性降低致病性结构域的诱变 毒力,增加细胞因子诱导和抗原呈递,并提供持久的 保护此外,每个突变的作用机制将是已知的, 每一个都将被特别设计成抵抗反转。我们将联合收割机的突变, 为每种病毒创建最佳疫苗株,然后研究它们在 多价制剂,对兽医疫苗开发至关重要, 人类制剂。我们将确定每种疫苗的保护相关性, 解决对脑炎病毒的交叉保护程度。首次与 甲病毒,具有已知机制的突变的单独和组合效应 将测试对病毒复制、疾病和免疫原性的影响, 动物

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WILLIAM B KLIMSTRA其他文献

WILLIAM B KLIMSTRA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WILLIAM B KLIMSTRA', 18)}}的其他基金

Viral and host factors in neuroinvasion of encephalitis alphaviruses
脑炎甲病毒神经侵袭的病毒和宿主因素
  • 批准号:
    10659110
  • 财政年份:
    2022
  • 资助金额:
    $ 48.44万
  • 项目类别:
Viral and host factors in neuroinvasion of encephalitis alphaviruses
脑炎甲病毒神经侵袭的病毒和宿主因素
  • 批准号:
    10389982
  • 财政年份:
    2022
  • 资助金额:
    $ 48.44万
  • 项目类别:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
针对脑炎甲病毒的减毒活疫苗的知情方法
  • 批准号:
    10027464
  • 财政年份:
    2020
  • 资助金额:
    $ 48.44万
  • 项目类别:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
针对脑炎甲病毒的减毒活疫苗的知情方法
  • 批准号:
    10188419
  • 财政年份:
    2020
  • 资助金额:
    $ 48.44万
  • 项目类别:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
针对脑炎甲病毒的减毒活疫苗的知情方法
  • 批准号:
    10674134
  • 财政年份:
    2020
  • 资助金额:
    $ 48.44万
  • 项目类别:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
针对脑炎甲病毒的减毒活疫苗的知情方法
  • 批准号:
    10636632
  • 财政年份:
    2020
  • 资助金额:
    $ 48.44万
  • 项目类别:
Development of a novel live attenuated vaccine for eastern equine encephalitis virus
新型东部马脑炎病毒减毒活疫苗的研制
  • 批准号:
    8869837
  • 财政年份:
    2015
  • 资助金额:
    $ 48.44万
  • 项目类别:
Characterization of microRNA binding sites in the eastern equine encephalitis virus 3'NTR
东部马脑炎病毒 3NTR 中 microRNA 结合位点的表征
  • 批准号:
    8966629
  • 财政年份:
    2014
  • 资助金额:
    $ 48.44万
  • 项目类别:
Characterization of microRNA binding sites in the eastern equine encephalitis virus 3'NTR
东部马脑炎病毒 3NTR 中 microRNA 结合位点的表征
  • 批准号:
    8821225
  • 财政年份:
    2014
  • 资助金额:
    $ 48.44万
  • 项目类别:
Molecular mechanisms of eastern equine encephalitis virus pathogenesis
东部马脑炎病毒发病的分子机制
  • 批准号:
    9594677
  • 财政年份:
    2012
  • 资助金额:
    $ 48.44万
  • 项目类别:

相似海外基金

AEROSOLS
气雾剂
  • 批准号:
    10101317
  • 财政年份:
    2024
  • 资助金额:
    $ 48.44万
  • 项目类别:
    EU-Funded
AEROSOLS - AIR QUALITY AND HEALTH IMPACT OF PRIMARY SEMI-VOLATILE AND SECONDARY PARTICLES AND THEIR ABATEMENT
气溶胶 - 一次半挥发性颗粒和二次颗粒对空气质量和健康的影响及其消除
  • 批准号:
    10092043
  • 财政年份:
    2024
  • 资助金额:
    $ 48.44万
  • 项目类别:
    EU-Funded
Molecular-level Understanding Of Atmospheric Aerosols (MUOAA 2024); Corsica, France; April 1-5, 2024
对大气气溶胶的分子水平理解(MUOAA 2024);
  • 批准号:
    2332007
  • 财政年份:
    2024
  • 资助金额:
    $ 48.44万
  • 项目类别:
    Standard Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
  • 批准号:
    NE/Y000021/1
  • 财政年份:
    2024
  • 资助金额:
    $ 48.44万
  • 项目类别:
    Research Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
  • 批准号:
    NE/Y000358/1
  • 财政年份:
    2024
  • 资助金额:
    $ 48.44万
  • 项目类别:
    Research Grant
Southern Ocean aerosols: sources, sinks and impact on cloud properties
南大洋气溶胶:来源、汇以及对云特性的影响
  • 批准号:
    DP240100389
  • 财政年份:
    2024
  • 资助金额:
    $ 48.44万
  • 项目类别:
    Discovery Projects
An AI-driven clinical washbasin unit that automatically disinfects pathogens, reduces aerosols and decreases healthcare-acquired infections by 70%
%20人工智能驱动%20临床%20洗脸盆%20单位%20%20自动%20消毒%20病原体,%20减少%20气溶胶%20和%20减少%20医疗保健获得性%20感染%20by%2070%
  • 批准号:
    83001507
  • 财政年份:
    2023
  • 资助金额:
    $ 48.44万
  • 项目类别:
    Innovation Loans
Cloudbusting with JWST: characterising aerosols, aurorae and chemistry in substellar atmospheresto the water cloud regime
使用 JWST 进行云消除:描述水云状态下恒星大气中的气溶胶、极光和化学成分
  • 批准号:
    ST/X001091/1
  • 财政年份:
    2023
  • 资助金额:
    $ 48.44万
  • 项目类别:
    Research Grant
INvestigating Home water and Aerosols' Links to opportunistic pathogen Exposure (INHALE): do consumer decisions impact pathogen exposure and virulence?
调查家庭用水和气溶胶与机会性病原体暴露(吸入)的联系:消费者的决定是否会影响病原体暴露和毒力?
  • 批准号:
    2326096
  • 财政年份:
    2023
  • 资助金额:
    $ 48.44万
  • 项目类别:
    Standard Grant
Bioactivated Aerosols for Combustion Product Capture
用于燃烧产物捕获的生物活性气溶胶
  • 批准号:
    10080253
  • 财政年份:
    2023
  • 资助金额:
    $ 48.44万
  • 项目类别:
    Small Business Research Initiative
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了